---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031636"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:41:55.525421+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Imunon Q3 net loss $6.1M ($0.87/sh); PLACCINE NHP data shows similar protection to mRNA vaccine

## Summary
- Net loss of $6.1M ($0.87 per share) vs $5.4M ($0.94 per share) in Q3 2021; operating expenses rose 21% to $6.3M.
- Cash and investments of $43.4M; expects cash runway into 2025.
- Phase I/II OVATION 2 study with GEN-1 fully enrolled (110 patients); topline results expected H1 2024.
- PLACCINE NHP study: viral clearance >90% in vaccinated vs controls; protection comparable to commercial mRNA vaccine.

## SEC filing metadata
- accession: 0001493152-22-031636
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/0001493152-22-031636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031636
- JSON: https://secwatch.observer/filing/0001493152-22-031636.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031636.txt

## Key facts
- Earnings Releases
  Imunon, Inc. reported financial results for the three-month and nine-month periods ended September 30, 2022.
  - Period: the three-month and nine-month periods ended September 30, 2022
  - Result: reported results
  source text: IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2022) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month periods ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/0001493152-22-031636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.